TheDapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial[48] findings indicate that irrespective of the presence of T2DM, patientsreceiving an SGLT-2 inhibitor had a significantly lower risk of HF deteriorationor cardiovascular death than the placebo group. Here, SLC5A2 is linked to type 2 diabetes mellitus.